Chester County News and Community Website
PHILADELPHIA, PA — The U.S. Food and Drug Administration (FDA) this week approved GSK‘s 200 mg/mL autoinjector of Benlysta (belimumab) for use in children aged five and older who are …
FDA Approves Benlysta Autoinjector for Pediatric Lupus Nephritis Treatment Read More PHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) has introduced the Linked by Lupus: Optimal Care Initiative, a new program designed to improve the lives of individuals affected by lupus, with …
GSK Launches Linked by Lupus Initiative to Advance Care and Support Read More PHILADELPHIA, PA — The U.S. Food and Drug Administration (FDA) has approved GSK’s Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with chronic obstructive pulmonary disease (COPD) with …
FDA Approves GSK’s Nucala for COPD Patients with Eosinophilic Phenotype Read More PHILADELPHIA, PA — The Advisory Committee on Immunization Practices (ACIP) has voted to expand the recommended use of GSK’s AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 50-59 who …
Expanded Recommendation for GSK’s AREXVY Vaccine Targets Adults at Higher Risk for Severe RSV Read More PHILADELPHIA, PA — The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the inclusion of GSK’s PENMENVY vaccine in the adolescent meningococcal …
CDC Panel Recommends GSK’s New PENMENVY Vaccine for Adolescents Read More PHILADELPHIA, PA — Global biopharma company GSK has awarded nearly $2 million in funding through its COiMMUNITY Initiative grant program to 15 organizations focused on improving adult immunization across the …
GSK Awards $2 Million in Grants to Boost Adult Immunization Read More
PHILADELPHIA, PA — The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for treating uncomplicated urinary tract infections (uUTIs) in adult women and adolescents …
FDA Approves GSK’s Blujepa as First New Oral Antibiotic for UTIs in 30 Years Read More
PHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of its RSV vaccine, AREXVY, over three full RSV …
GSK’s AREXVY Vaccine Shows Promising Results Across Three RSV Seasons Read More